shadow_tr

Prostate Studies
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -


UAB 1336
A Phase 2 Trial of Carfilzomib for Metastatic Castration-Resistant Prostate Cancer Following Chemotherapy and Androgen Pathway Inhibitors
More Information


EC1169-01
A Phase I Study of a Prostate-Specific Membrane Antigen Targeting-Tubulysin Conjugate EC1169 in Patients With Recurrent Metastatic, Castration-Resistant Prostate Cancer (mCRPC)
More Information


REASSURE
Radium-223 Alpha Emitter Agent in Safety Study in mCRPC Population for Long-Term Evaluation
More Information


Sotio SP005
A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
More Information

P12-1
A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer (PREDICT)
More Information

BAY 16544
A Randomized Open-label Phase IIa Study Evaluating the Efficacy and Safety of Radium-223 Dichloride in Combination with Abiraterone Acetate or Enzalutamide in Subjects with CRPC Who Have Bone Metastases
More Information


RTOG 0815
A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer
More Information


RTOG 0924
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy In Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
More Information


TUHC 07/25/13 - Genetics of Prostate Cancer

BAY 15396
A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)
More Information

SWOG S1216
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
More Information



1430 Tulane Ave, New Orleans, LA 70112 504-988-5331 medsch@tulane.edu